Guardant Health is in a powerful sustained uptrend, with the stock surging 223.9% over the past year, dramatically outperforming the S&P 500's 16.5% gain. The current price of $147.33 sits at 84.7% of its 52-week range ($40.35-$174.08), indicating strong momentum but not yet at overbought extremes near the high. This positioning suggests the uptrend remains intact with potential for further upside, though the stock is approaching resistance. Short-term momentum is accelerating, with the 1-month price change of +7.6% and 3-month change of +65.7%, both significantly outpacing the S&P 500's respective gains of 0.8% and 3.5%. The 1-month relative strength of +6.8% confirms continued buying pressure, and the 3-month trend aligns with the 1-year uptrend, showing no divergence. The stock's beta of 1.59 indicates 59% more volatility than the market, amplifying both upside and downside moves. Key support lies at the 52-week low of $40.35, while resistance is at the 52-week high of $174.08. A breakout above $174.08 would signal a continuation of the uptrend, while a breakdown below recent support near $130 could indicate a pullback. The high beta suggests aggressive position sizing is warranted only for risk-tolerant investors.

Revenue is growing rapidly, with Q1 2026 revenue of $301.7 million, up 48.3% year-over-year from $203.5 million in Q1 2025. This marks an acceleration from the 14.0% YoY growth in Q2 2025 ($232.1 million) and 30.0% in Q3 2025 ($265.2 million). The Oncology segment contributed $205.0 million, Screening $41.6 million, and Biopharma & Data $53.0 million, with Screening showing strong potential as a growth driver. The accelerating top-line trend supports the investment case for a company gaining commercial traction. The company remains unprofitable, with a net loss of $112.1 million in Q1 2026, though the net margin improved to -37.2% from -46.8% in Q1 2025. Gross margin is healthy at 65.2% in Q1 2026, stable from 63.3% a year ago, indicating good unit economics. Operating margin was -40.2%, reflecting high R&D ($91.0 million) and SG&A ($227.1 million) expenses, but the trend is improving from -54.6% in Q1 2025. The trajectory toward profitability is positive as revenue scales. Guardant Health has a strong liquidity position with a current ratio of 4.84 and cash of $1.1 billion as of Q1 2026, up from $489 million at year-end 2025. However, the company is not yet free cash flow positive, with TTM FCF of -$224.8 million, and it relies on external financing, as seen by $351 million in common stock issued in Q4 2025. The debt-to-equity ratio is negative (-17.2) due to negative equity, indicating high financial leverage, but the large cash balance provides a buffer. ROE is extremely high at 419%, but this is distorted by negative equity; ROA of -17.1% better reflects operational inefficiency.